INVASIVE INTERVENTIONS IN STRUCTURAL HEART DISEASES: COMPREHENSIVE TECHNIQUES

Invasive Interventions in Structural Heart Diseases-kapak

EPIDEMIOLOGY AND PREVALENCE

Hande Seymen

Bolu İzzet Baysal State Hospital, Department of Cardiology, Bolu, Türkiye

Seymen H. Epidemiology and Prevalence. In: Tanık VO, Özlek B, editors. Invasive Interventions in Structural Heart Diseases: Comprehensive Techniques. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.3-14.

ABSTRACT

Structural heart diseases are an important area of interest in cardiology and can be evaluated under two subheadings: acquired and congenital heart diseases. Aortic stenosis, mitral stenosis, mitral regurgitation, tricuspid regurgitation, and paravalvular leaks are among the acquired heart diseases. Congenital heart diseases include pulmonary stenosis, atrial septal defect (ASD), ventricular septal defect (VSD), patent ductus arteriosus (PDA), and coronary fistulas. Although structural heart diseases were predominantly treated surgically in the past, percutaneous/transcatheter treatments are performed by more and more cardiologists with the effect of rapid developments in technology and increasing device quality and diversity, and in some areas, surgical treatment has been surpassed. With the development of imaging techniques, more accurate evaluations are made before the intervention, and the success rate is increasing.

Keywords: Structural heart diseases; Prevalence; Epidemiology

Referanslar

  1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. [Crossref]
  2. Mensah GA, Roth GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. J Am Coll Cardiol. 2019;74(20):2529-32. [Crossref]  [PubMed]
  3. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341(3):142-7. [Crossref]  [PubMed]
  4. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N. Engl. J. Med. 2012;366:1686-1695. [Crossref]  [PubMed]
  5. Tay ELW, Ngiam JN, Kong WK, Poh KK. Management of severe aortic stenosis: the Singapore and Asian perspective. Singapore Med J. 2018;59(9):452-4. [Crossref]  [PubMed]  [PMC]
  6. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106(24):3006-8. [Crossref]  [PubMed]
  7. Carroll JD, Mack MJ, Vemulapalli S, Herrmann HC, Gleason TG, Hanzel G, et al. STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2020;76(21):2492-516. [Crossref]  [PubMed]
  8. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597-607. [Crossref]  [PubMed]
  9. Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet Lond Engl. 2015 Jun 20;385(9986):2485-91. [Crossref]  [PubMed]
  10. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic- valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187-98. [Crossref]  [PubMed]
  11. Reardon MJ, Adams DH, Kleiman NS, Yakubov SJ, Coselli JS, Deeb GM, et al. 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2015;66(2):113-21. [Crossref]
  12. Sorysz D, Januszek R, Sowa-Staszczak A, Grochowska A, Opalińska M, Bagieński M, et al. The Usefulness of [18F] F-Fluorodeoxyglucose and [18F]F-Sodium Fluoride Positron Emission Tomography Imaging in the Assessment of Early-Stage Aortic Valve Degeneration after Transcatheter Aortic Valve Implantation (TAVI)-Protocol Description and Preliminary Results. J Clin Med. 2021;10(3):431. [Crossref]  [PubMed]  [PMC]
  13. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24(13):1231-43. [Crossref]  [PubMed]
  14. Andell P, Li X, Martinsson A, Andersson C, Stagmo M, Zöller B, et al. Epidemiology of valvular heart disease in a Swedish nationwide hospital-based register study. Heart Br Card Soc. 2017;103(21):1696-703. [Crossref]  [PubMed]  [PMC]
  15. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632. [Link]
  16. Sud K, Agarwal S, Parashar A, Raza MQ, Patel K, Min D, et al. Degenerative Mitral Stenosis: Unmet Need for Percutaneous Interventions. Circulation. 2016;133(16):1594-604. [Crossref]  [PubMed]
  17. Nobuyoshi M, Arita T, Shirai S ichi, Hamasaki N, Yokoi H, Iwabuchi M, et al. Percutaneous Balloon Mitral Valvuloplasty. Circulation. 2009;119(8):e211-9. [Crossref]
  18. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. The Lancet. 2006;368(9540):1005-11. [Crossref]  [PubMed]
  19. Roth GA, Mensah GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risks: A Compass for Global Action. J Am Coll Cardiol. 2020;76(25):2980-1. [Crossref]  [PubMed]
  20. Atianzar K, Zhang M, Newhart Z, Gafoor S. Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip. 2019 Jan 22. [Crossref]  [PubMed]  [PMC]
  21. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. 2018;379(24):2297-306. [Crossref]  [PubMed]
  22. Stone GW, Abraham WT, Lindenfeld J, Kar S, Grayburn PA, Lim DS, et al. Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation. N Engl J Med. 2023;388(22):2037-48. [Crossref]  [PubMed]
  23. Writing Committee Members, Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021;77(4):450-500. [Link]
  24. Piriou N, Al Habash O, Donal E, Senage T, Le Tourneau T, Pattier S, et al. The MITRA-HR study: design and rationale of a randomised study of MitraClip transcatheter mitral valve repair in patients with severe primary mitral regurgitation eligible for high-risk surgery. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2019;15(4):e329-35. [Crossref]  [PubMed]
  25. McCarthy PM, Whisenant B, Asgar AW, Ailawadi G, Hermiller J, Williams M, et al. Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are Candidates for Surgery: Design and Rationale of the REPAIR MR Trial. J Am Heart Assoc. 2023;12(4):e027504. [Crossref]  [PubMed]  [PMC]
  26. Vieitez JM, Monteagudo JM, Mahia P, Perez L, Lopez T, Marco I, et al. New insights of tricuspid regurgitation: a large-scale prospective cohort study. Eur Heart J Cardiovasc Imaging. 2021;22(2):196-202. [Crossref]  [PubMed]
  27. Praz F, Muraru D, Kreidel F, Lurz P, Hahn RT, Delgado V, et al. Transcatheter treatment for tricuspid valve disease. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2021;17(10):791-808. [Crossref]  [PubMed]  [PMC]
  28. Adamo M, Chioncel O, Benson L, Shahim B, Crespo-Leiro MG, Anker SD, et al. Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: An analysis from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2023;25(7):1061-71. [Crossref]  [PubMed]
  29. De la Espriella R, Santas E, Chorro FJ, Miñana G, Soler M, Bodí V, et al. Functional tricuspid regurgitation and recurrent admissions in patients with acute heart failure. Int J Cardiol. 2019;291:83-8. [Crossref]  [PubMed]
  30. Nickenig G, Kowalski M, Hausleiter J, Braun D, Schofer J, Yzeiraj E, et al. Transcatheter Treatment of Severe Tricuspid Regurgitation With the Edge-to-Edge Mitra-Clip Technique. Circulation. 2017;135(19):1802-14. [Crossref]  [PubMed]
  31. Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, et al. Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis: An Expert Statement. J Am Coll Cardiol. 2017 Apr 25;69(16):2067-87. [Crossref]  [PubMed]
  32. Hwang HY, Choi JW, Kim HK, Kim KH, Kim KB, Ahn H. Paravalvular Leak After Mitral Valve Replacement: 20-Year Follow-Up. Ann Thorac Surg. 2015;100(4):1347-52. [Crossref]  [PubMed]
  33. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol. 2000;36(4):1152-8. [Crossref]  [PubMed]
  34. Bernard S, Yucel E. Paravalvular Leaks-From Diagnosis to Management. Curr Treat Options Cardiovasc Med. 2019;21(11):67. [Crossref]  [PubMed]
  35. van der Linde D, Konings EEM, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJM, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58(21):2241-7. [Crossref]  [PubMed]
  36. Lancellotti P, Zamorano JL, Habib G, Badano L. The EACVI Textbook of Echocardiography. Oxford University Press; 2017:671. [Crossref]
  37. Schicchi N, Secinaro A, Muscogiuri G, Ciliberti P, Leonardi B, Santangelo T, et al. Multicenter review: role of cardiovascular magnetic resonance in diagnostic evaluation, pre-procedural planning and follow-up for patients with congenital heart disease. Radiol Med (Torino). 2016;121(5):342-51. [Crossref]  [PubMed]
  38. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2009;22(1):1-23; quiz 101-2. [Crossref]  [PubMed]
  39. Rao PS. Indications for balloon pulmonary valvuloplasty. Am Heart J. 1988;116(6Pt1):1661-2. [Crossref]  [PubMed]
  40. Marchini F, Meossi S, Passarini G, Campo G, Pavasini R. Pulmonary Valve Stenosis: From Diagnosis to Current Management Techniques and Future Prospects. Vasc Health Risk Manag. 2023;19:379-90. [Crossref]  [PubMed]  [PMC]
  41. Bonhoeffer P., Boudjemline Y., Saliba Z., et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet. 2000;356(9239):1403-1405. [Crossref]  [PubMed]
  42. Chelu RG, Horowitz M, Sucha D, Kardys I, Ingremeau D, Vasanawala S, et al. Evaluation of atrial septal defects with 4D flow MRI-multilevel and inter-reader reproducibility for quantification of shunt severity. Magma N Y N. 2019;32(2):269-79. [Crossref]  [PubMed]  [PMC]
  43. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014;130(9):749-56. [Crossref]  [PubMed]
  44. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(14):e698-800. [Crossref]
  45. Mills NL, King TD. Nonoperative closure of left-toright shunts. J Thorac Cardiovasc Surg. 1976;72(3):371-8. [Crossref]  [PubMed]
  46. ung S.Y., Choi J.Y. Transcatheter closure of atrial septal defect: Principles and available devices. J. Thorac. Dis. 2018;10((Suppl. S24)):S2909-S2922. [Crossref]  [PubMed]  [PMC]
  47. Cresti A, Giordano R, Koestenberger M, Spadoni I, Scalese M, Limbruno U, et al. Incidence and natural history of neonatal isolated ventricular septal defects: Do we know everything? A 6-year single-center Italian experience follow-up. Congenit Heart Dis. 2018;13(1):105-12. [Crossref]  [PubMed]
  48. Zhao QM, Niu C, Liu F, Wu L, Ma XJ, Huang GY. Spontaneous Closure Rates of Ventricular Septal Defects (6,750 Consecutive Neonates). Am J Cardiol. 2019;124(4):613-7. [Crossref]  [PubMed]
  49. Alizadeh B. Transcatheter Closure of Congenital VSDs: Tips and Tricks. In: Angiography. [Link]
  50. Hoffman JIE, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12):1890-900. [Crossref]  [PubMed]
  51. Hoffman JIE, Kaplan S, Liberthson RR. Prevalence of congenital heart disease. Am Heart J. 2004;147(3):425-39. [Crossref]  [PubMed]
  52. Sharfi MH, Alghamdi AH, Mashali MH, Helel AM, Arfi MA. Current Advances in Transcatheter Intervention for Children Born with Congenital Heart Defects: A Review of Literature. J Biosci Med. 2021;9(7):219-30. [Crossref]
  53. Lim JJ, Jung JI, Lee BY, Lee HG. Prevalence and types of coronary artery fistulas detected with coronary CT angiography. AJR Am J Roentgenol. 2014;203(3):W237-243. [Crossref]  [PubMed]
  54. Oto MA, Aytemir HY& K. Percutaneous approaches to closure of coronary artery fistulas. Interv Cardiol. 2011;3(1):79-90. [Link]